Sector News

Why to Keeping Eye on Edwards Lifesciences Corporation (EW), American Tower Corporation (AMT)?

July 28, 2017
Life sciences

Edwards Lifesciences Corporation (NYSE:EW) gained 0.65% with the closing price of $116.36. The overall volume in the last trading session was 3.53 million shares.

Company Growth Evolution:

ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business. Investors who are keeping close eye on the stock of Edwards Lifesciences Corporation (NYSE:EW) established that the company was able to keep return on investment at 17.30 in the trailing twelve month while Reuters data showed that industry’s average stands at 8.54 and sector’s optimum level is -8.37.

Edwards Lifesciences Corporation (EW) have shown a high EPS growth of 21.40% in the last 5 years and has earnings rose of 16.20% yoy. Analysts have a mean recommendation of 2.00 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). The stock appeared $121.75 above its 52-week highs and is down -2.56% for the last five trades. The stock ended last trade at $116.36 a share and the price is up more than 24.18% so far this year. The company maintains price to book ratio of 8.87 vs. an industry average at 3.75. Its sales stood at 12.00% a year on average in the period of last five years. A P/B ratio of less than 1.0 can indicate that a stock is undervalued, while a ratio of greater than 1.0 may indicate that a stock is overvalued.

American Tower Corporation (NYSE:AMT) ended its day at $134.86 with the rising stream of -2.18% and its total traded volume was 2.92 million shares more than the average volume.

Returns and Valuations for American Tower Corporation (NYSE:AMT)

American Tower Corporation (NYSE:AMT), maintained return on investment for the last twelve months at 3.76, higher than what Reuters data shows regarding industry’s average. The average of this ratio is 8.62 for the industry and sector’s best figure appears 0.42. American Tower Corporation (NYSE:AMT), at its latest closing price of $134.86, it has a price-to-book ratio of 8.58, compared to an industry average at 4.44. A lower P/B ratio could mean that the stock is undervalued. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately.

American Tower Corporation (NYSE:AMT), stock is trading $138.00 above the 52-week high and has displayed a high EPS growth of 14.80% in last 5 years. The 1 year EPS growth rate is 40.70% . Its share price has risen 7.23% in three months and is down -1.01% for the last five trades. The average analysts gave this company a mean recommendation of 1.70.

By Jerome Gibson

Source: Stock News Journal

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach